• Publications
  • Influence
Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
The impact of comorbidities, as measured by the HCT-CI and CIRS, on survival and tolerance of CAR T-cell therapy in patients with r/r DLBCL treated off clinical protocols is reported. Expand
Thoracic sarcoidosis versus tuberculosis: Need for a multi-disciplinary approach
  • A. Mian, A. Ray
  • Medicine
  • The Indian journal of radiology & imaging
  • 1 April 2018
The algorithm, proposed by the authors, unifies clinical, radiological, laboratory, and pathological evidence to serve as an effective diagnostic tool. Expand
Recurrent drug eluting stent in-stent restenosis: A state-of-art review of pathophysiology, diagnosis and management.
The understanding of the risk factors, invasive and non-invasive imaging techniques, therapeutic options and gaps in present knowledge for the management of R-ISR are discussed. Expand
Cavitary Lung Lesions in a Difficult-To-Treat Asthma Patient.
An interesting case of severe asthma who was not showing satisfactory response to standard treatment and was found to be suffering from allergic bronchopulmonary aspergillosis (ABPA), which was investigated further and found to have chronic pulmonary asperGillosis in the form of chronic cavitary pulmonary as pergillsosis (CCPA) and asPergilloma. Expand
Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
Outcomes for adult BL in this real-world analysis appeared more modest compared with results of clinical trials and smaller series and prognostic factors at diagnosis identified patients with divergent survival rates. Expand
The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review
It is concluded that SARS-CoV-2 infected patients with elevated D-dimer levels have worse clinical outcomes (all-cause mortality, ICU admission or ARDS) and thus measurement of D-dimers can guide in clinical decision making. Expand
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
  • A. Mian, B. Hill
  • Medicine
  • Expert opinion on biological therapy
  • 10 February 2021
While data on long-term outcomes of CAR T-cell therapy in MCL patients are needed, brexu-cel has shown remarkable clinical activity and its regulatory approval has immediate practice-changing implications in this highly aggressive malignancy. Expand
Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
This intent-to treat (ITT) analysis compared the outcomes of patients at the authors' center with R/R B-cell lymphoma who received Axi-cel with those for whom AxI-cel therapy was intended but not administered, in order to identify factors that may limit its use in this population. Expand
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis
Additional strategies are needed to ensure all LBCL patients for whom chimeric antigen receptor (CAR) T-cell therapy is prescribed can receive this treatment, as limited data on real-world outcomes of axi-cel therapy for relapsed/refractory large B-cell lymphoma are limited. Expand
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
A large multicenter retrospective study of newly diagnosed adult BL cases and treatment patterns across 26 US CCs over a recent 9 year period and also determined survival rates & prognostication. Expand